Myeloma UK news // 16th May 2018
Myeloma UK news // 16th May 2018
After 12 years as Chairman of Myeloma UK, Judy Dewinter has announced that she will be stepping down from the board and has agreed to take up a new position as President of the organisation, which will see her taking on an advisory and ambassadorial role.
She will hand over to Marc Gordon, who has been on the board and Treasurer since 2012. Both roles will come into effect on 1st January 2019.
Myeloma UK was established 21 years ago and I am so proud of what we have achieved during this time. As a patient myself, I took on the chairmanship 12 years ago because I believed in the vision – to accelerate the discovery, development and access to new treatments. From the outset, we worked hand in hand with the myeloma community – our doctors, nurses, researchers and patients, in collaboration with government and industry – and the situation is now very different. Overall survival rates have increased dramatically, and patients are living longer than they ever dared to imagine.
I feel privileged to have led the board over the last 12 years and it is now time for a new Chairman to take over. Marc has been on the board, as our Treasurer, since 2012. With his experience as a partner of a highly successful investment management firm, he has combined his business acumen with a strong desire to help myeloma patients, borne out of his very close relationship with two myeloma sufferers. He has huge integrity and has earned the respect of the whole team for his tremendous insight, honesty and compassion. I feel confident that, under his leadership, we will continue to go from strength to strength. I look forward to supporting him, and our exceptional Chief Executive, Rosemarie Finley, in my capacity as President.
Judy has been a remarkable Chairman and she has made an outstanding contribution to Myeloma UK. Having been diagnosed with myeloma 20 years ago, Judy chose to channel her business expertise, her determination and sharp focus into helping build an organisation that could extend the lives of myeloma patients, including her own. The impact she has had on the organisation has been enormous. We are delighted that she has agreed to become Myeloma UK’s President.
As the new Chairman, I will be committed to ensuring that the organisation continues to provide essential services to patients and their families, combined with an emphasis on research. Maintaining key relationships with healthcare professionals, industry and regulators will also remain a key priority. We will be focused on driving forward our strategy and keeping patients at the heart of everything we do. We are fortunate to have a brilliant team, an outstanding Chief Executive in Rosemarie Finley and a soon to be new President in Judy. I am tremendously excited about what the future holds and am looking forward to taking over the role of Chairman in the new year.
I cannot thank Judy enough for what she has achieved on behalf of myeloma patients. It has been a privilege to work with her and I am delighted that she will continue to support us in her new role as President. I also look forward to working closely with Marc as he now begins his transition to Chairman. The organisation will benefit greatly from his leadership skills, professional experience and pioneering spirit. We know there is a lot more to do and we will continue to focus all our efforts on delivering our strategy for the benefit of myeloma patients.